- Home
- ESEA vs ERAS Comparison
ESEA vs ERAS Comparison
Compare ESEA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- ERAS
- Stock Information
- Founded
- ESEA 2005
- ERAS 2018
- Country
- ESEA Greece
- ERAS United States
- Employees
- ESEA N/A
- ERAS N/A
- Industry
- ESEA Marine Transportation
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ESEA Consumer Discretionary
- ERAS Health Care
- Exchange
- ESEA Nasdaq
- ERAS Nasdaq
- Market Cap
- ESEA 432.8M
- ERAS 439.7M
- IPO Year
- ESEA 2006
- ERAS 2021
- Fundamental
- Price
- ESEA $55.52
- ERAS $2.42
- Analyst Decision
- ESEA Strong Buy
- ERAS Buy
- Analyst Count
- ESEA 1
- ERAS 6
- Target Price
- ESEA $62.00
- ERAS $3.67
- AVG Volume (30 Days)
- ESEA 44.7K
- ERAS 2.5M
- Earning Date
- ESEA 11-19-2025
- ERAS 11-11-2025
- Dividend Yield
- ESEA 5.04%
- ERAS N/A
- EPS Growth
- ESEA 0.63
- ERAS N/A
- EPS
- ESEA 17.09
- ERAS N/A
- Revenue
- ESEA $221,034,167.00
- ERAS N/A
- Revenue This Year
- ESEA $9.61
- ERAS N/A
- Revenue Next Year
- ESEA $1.86
- ERAS N/A
- P/E Ratio
- ESEA $3.25
- ERAS N/A
- Revenue Growth
- ESEA 7.73
- ERAS N/A
- 52 Week Low
- ESEA $24.58
- ERAS $1.01
- 52 Week High
- ESEA $66.00
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- ESEA 42.60
- ERAS 61.69
- Support Level
- ESEA $53.60
- ERAS $2.28
- Resistance Level
- ESEA $58.36
- ERAS $2.65
- Average True Range (ATR)
- ESEA 2.47
- ERAS 0.22
- MACD
- ESEA -0.40
- ERAS -0.00
- Stochastic Oscillator
- ESEA 27.39
- ERAS 51.88
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.